

ESTIMATION OF THE EMAX MODEL

GIACOMO ALETTI

ADAMSS Center, Università degli Studi di Milano, Milan 20133, MI, Italy

NANCY FLOURNOY

Department of Statistics, University of Missouri, Columbia 65211, MO, United States of America

CATERINA MAY

Dipartimento di Studi per l'Economia e l'Impresa, Università del Piemonte Orientale, Novara 28100, NO, Italy

Department of Mathematics, King's College London, London WC2R 2LS, Strand, United Kingdom

CHIARA TOMMASI

Department of Economics, Management and Quantitative Methods, Università degli Studi di Milano, Milan 20122, MI, Italy

ABSTRACT. This study focuses on the estimation of the Emax dose-response model, a widely utilized framework in clinical trials, agriculture, and environmental experiments. Existing challenges in obtaining maximum likelihood estimates (MLE) for model parameters are often ascribed to computational issues but, in reality, stem from the absence of MLE. Our contribution provides a new understanding and control of all the experimental situations that practitioners might face, guiding them in the estimation process. We derive the exact MLE for a three-point experimental design and we identify the two scenarios where the MLE fails. To address these challenges, we propose utilizing Firth's modified score, providing its analytical expression as a function of the experimental design. Through a simulation study, we demonstrate that, in one of the problematic cases, the Firth modification yields a finite estimate. For the remaining case, we introduce a design-correction strategy akin to a hypothesis test.

E-mail addresses: giacomo.aletti@unimi.it, flournoyn@missouri.edu, caterina.may@uniupo.it, chiara.tommasi@unimi.it.

Key words and phrases. nonlinear regression, Emax model, maximum likelihood, experimental design, small sample, score modification, optimal design.

CONTENTS

| | |
|---|----|
| 1. Introduction | 2 |
| 2. Model and notation | 3 |
| 2.1. Parameter space and interpretation | 4 |
| 2.2. Reparametrization when $a > 0$ | 5 |
| 3. Maximum likelihood estimator | 5 |
| 3.1. Analytic solution of the MLE: Data with increasing concave shape | 6 |
| 3.2. Cases when the MLE does not exist | 8 |
| 4. Score modification according to Firth's theory | 13 |
| 4.1. The Score Vector | 15 |
| 4.2. Score Modification A_t | 16 |
| 5. Firth's modification and design-based solution, for Cases 1 and 2 | 18 |
| 5.1. Design choice based on an hypothesis test to overcome Case 1 | 19 |
| 6. Practical guidelines and conclusion | 20 |
| Appendix A. Auxiliary results | 20 |
| References | 22 |

1. INTRODUCTION

The Emax model is well-characterized in the literature and widely used in several fields, clinical trials, biochemistry, agriculture and environmental experiments (e.g., Bretz et al. (2010); Baker (2010); Baker et al. (2016); Han et al. (2011); Holford and Sheiner (1981); MacDougall (2006); Denney et al. (2017); Rath et al. (2022)). The Emax model is an extension of the widely used Michaelis-Menten model (Michaelis et al., 1913). In the literature it is often presented with three or four parameters (also called the four parameter logistic model). In this study, we consider the three parameter version which is often used in dose-response studies where one often assumes the response mean can be described by a simple concave function that increases monotonically with a covariate $x \in \mathcal{X}$ such as dose or stress (see Leonov and Miller (2009) and Chen et al. (2023)). Other aspects of this model have been studied in Dette et al. (2010); Dragalin et al. (2010); Flournoy et al. (2021).

Although the maximum likelihood estimates (MLEs) of the model parameters are asymptotically consistent, the uncertainty due to finite samples may lead to the non-existence of the MLE. This problem is already known and, actually, there is a long literature on the problems of convergence of the estimation algorithms for the Emax parameters; see, for example, Fedorov and Leonov (2013), Flournoy et al. (2020) and Chen et al. (2023). We analyze the same problem not from a numerical point of view but theoretically, showing the geometrical aspects behind the application of the likelihood method in the Emax model. More specifically, in this work, we consider three-points experimental designs. This is a common choice in experimental practice and the D-optimal design is a particular case of it. Provided that the mean observations at the design support points respect a natural geometric condition (that is, increasing concave shape), we are able to give the analytic expression of the MLE for the Emax model as a function of the data. In addition, we are able to prove that if the observations do not respect this geometrical condition then the MLE does not exist. Furthermore, we identify two

different scenarios (with several sub-cases) where the MLE fails and provide the probabilities of these unlucky cases.

To handle the issue of the MLE non-existence, at first we suggest to use the roots of Firth modified score equations (see Firth (1993)). In more detail, Firth (1993) developed a general method to reduce the bias of the MLE by modifying the score function. The roots of Firth modified score equations result in first-order unbiased estimators, herein called Firth-modified estimators (see also, Kosmidis and Firth (2009b,a)). But, more importantly for our goal of finding a finite estimate, Firth (1993, sect 3.3) shows that his method may solve the problem of the non-existence of the MLE even with moderate sample sizes.

To apply Firth's method given an experimental design, we derive the analytical expression of Firth's correction for the score function of the Emax model as a function of any design. It is worth noting that the Firth modified score actually leads to a finite estimate in one of the scenarios where the maximum likelihood method fails. However, in the other scenario Firth's method fails too.

In this last case, from geometrical considerations, we suggest a kind of design-correction, i.e. we identify the region where an additional experimental point should be selected in order to obtain a finite estimate. Let us note that this design-correction is proved to be equivalent to a hypothesis test on the most critical parameter of the Emax model.

In Section 2 we give the notation and the parameterization of the Emax model. Section 3 concerns the analytic expression of the MLE (with the conditions of its existence), and the list of the bad scenarios where the MLE does not exist. In Section 4 we provide the explicit formula for the Firth correction of the Emax score function. In Section 5 we face the bad scenarios, showing when Firth method succeeds as well as when a design strategy is necessary to control the problem. Finally Section 6, which concludes the paper, provides a practical guideline for an experimenter resulting from our theoretical results.

2. MODEL AND NOTATION

The *Emax* model is $y = \eta(x, \theta) + \varepsilon$, where y denotes a response at the dose $x \in \mathcal{X} = [a, b]$, $a \geq 0$ and $b \geq a$ are the lowest and the highest admissible doses, ε is a Gaussian random error, and $\theta = (\theta_0, \theta_1, \theta_2)^T$ is a vector of unknown parameters that belongs to a parameter space that makes the response mean

$$(1) \quad \eta(x, \theta) = \theta_0 + \theta_1 \frac{x}{x + \theta_2}$$

an increasing and concave curve (see Section 2.1).

An experimental design is defined as a finite discrete probability distribution over \mathcal{X} :

$$(2) \quad \xi = \left\{ \begin{array}{ccc} x_1 & \cdots & x_M \\ \omega_1 & \cdots & \omega_M \end{array} \right\},$$

where x_i denotes the i th experimental point, or treatment dose, that may be used in the study and ω_i is the proportion of experimental units to be taken at that point; $\omega_i \geq 0$ with $\sum_{i=1}^M \omega_i = 1$, $i = 1, \dots, M$ and M is finite.

Assuming that at the dose x_i we observe $n_i = \omega_i \cdot n$ independent responses, y_{i1}, \dots, y_{in_i} (for $i = 1, \dots, M$), the most common estimate of θ is the maximum likelihood estimator (MLE). It is well known that, to improve the precision of the

MLE, we should apply a D-optimal design, since it minimizes the generalized asymptotic variance of the MLE for θ . General references on optimal design of experiments include Fedorov (1972), Atkinson et al. (2007) and Silvey (2013), while Fedorov and Leonov (2013) is specific to optimal designs for nonlinear response models.

Let

$$I(\xi; \theta) = \int_{\mathcal{X}} \nabla \eta(x, \theta) \nabla \eta(x, \theta)^T d\xi(x)$$

be the Fisher information matrix of an experiment with design ξ under model (1), where $\nabla \eta(x, \theta)$ denotes the gradient of the mean response $\eta(x, \theta)$ with respect to θ . The D-optimal design for Emax model (provided by Dette et al. (2010)) is

$$\xi^*(\theta) = \arg \max_{\xi \in \Xi} \text{Det}[I(\xi, ; \theta)] = \left\{ \begin{array}{ccc} a & x^*(\theta_2) & b \\ 1/3 & 1/3 & 1/3 \end{array} \right\},$$

where Ξ is the set of all possible designs and

$$(3) \quad x^*(\theta_2) = \frac{b(a + \theta_2) + a(b + \theta_2)}{(a + \theta_2) + (b + \theta_2)}.$$

The design $\xi^*(\theta)$ is locally optimal because it depends on the unknown parameter value θ , due to the non-linearity of $\eta(x, \theta)$.

2.1. Parameter space and interpretation. For what will be discussed in this section, it is important to note that on the Cartesian plane the equation $y = \eta(x, \theta)$ given by model (1) is an hyperbola with the horizontal asymptote $y = \theta_0 + \theta_1$ and the vertical asymptote $x = -\theta_2$. The Emax response mean curve is the concave branche of this hyperbola.

It is often natural to assume that the dose $x = 0$ is the lower dose admissible, that is, the inferior limit of the experimental space is $a = 0$. In the Emax model, if $a = 0$, then θ_0 represents the response at dose $x = 0$ (placebo effect), $\theta_1 > 0$ is the asymptotic maximum effect attributable to the drug (for an infinite dose) and $\theta_2 > 0$ is the dose which produces the half of the maximum effect. By considering this parameter space for $x \in [0, b]$, all the concave branches of the hyperbola can be fitted in the model.

To solve the computational problems and to ensure the existence of the MLE, several authors have bounded the space of the non-linear parameter θ_2 in a positive compact set; for instance, Dette et al. (2012) consider $\theta_2 \in [0.015; 1500]$. Unfortunately, in this way some parameters values, that gives response curve that may fit better the observed data, are excluded. In this paper we solve any computational problem by providing an analytic solution of the MLE for $\theta_2 > 0$, together with the exact conditions of its existence (see Section 3).

When the lower dose admissible is $a > 0$, the parameter interpretation given above fails. In addition, if $a > 0$ and $\theta_2 > 0$, all the admissible response curves with vertical asymptote in $(0, a)$ are excluded. These curves may approximate better the observed data, and hence the parametric domain of θ_2 should be extended to ensure best fit. This is motivated in detail in Section 2.2 by introducing a suitable reparametrization of the model. The conditions of existence and the analytic solution for the MLE are provided in Section 3 also in this case.

2.2. Reparametrization when $a > 0$. In some situations, due to ethical concerns, patient exposure to placebo is not feasible, and then the mean response curve $E(Y|X = x)$ is considered in a domain $\mathcal{X} = [a, b]$, $a > 0$. Model (1) can be rewritten as

$$(4) \quad E(Y|X = x) = \eta(x - a, \tilde{\theta}) = \tilde{\theta}_0 + \tilde{\theta}_1 \frac{(x - a)}{(x - a) + \tilde{\theta}_2},$$

where

$$(5) \quad \tilde{\theta}_0 = \theta_0 + a \frac{\theta_1}{\theta_2 + a}, \quad \tilde{\theta}_1 = \theta_1 - a \frac{\theta_1}{\theta_2 + a}, \quad \tilde{\theta}_2 = \theta_2 + a.$$

Model (4) represents an Emax model in a new parametrization, with a change in the coordinate to $\tilde{x} = x - a$. Notice that the same parametrization has been considered by Chen et al. (2023). An experimenter would be reasonably interested in estimating the new parameters, since $\tilde{\theta}_0$ is the mean response for the lower dose $x = a$, $\tilde{\theta}_1$ is the asymptotic maximum effect attributable to the drug with respect to the response at the minimal dose, and $\tilde{\theta}_2$ is the dose added to a which produces the half of the maximum effect. Likewise the case $a = 0$, the constraints $\tilde{\theta}_1 > 0$, $\tilde{\theta}_2 > 0$ identify all the increasing and concave branches of hyperbola.

The next Proposition 2.1 shows that the Emax mean response curves are not a compact set; roughly speaking, some response curves obtained as limit of curves in model (1) do not belong to the same model. As a consequence, there are situations when the data are such that it is not possible to find out an ‘‘Emax’’ mean response curve that maximizes the likelihood, which is instead maximized by one of the three limit cases listed in Proposition 2.1. Consider now $\mathcal{X} = [a, b]$, $a \geq 0$, and the reparametrization (4) (which coincides with the standard parametrization when $a = 0$).

Proposition 2.1. *The set of increasing and concave branches of hyperbola on \mathcal{X} is not a compact set, since the limit class contains other bounded functions on \mathcal{X} , which precisely are*

- (1) *the strictly increasing straight lines $\tilde{y} = m \tilde{x} + q$, as limit of $\eta(\tilde{x}, \tilde{\theta})$ when, for instance, $\tilde{\theta}_0 = q$, $\tilde{\theta}_1 = m \tilde{\theta}_2$ and $\tilde{\theta}_2 \rightarrow \infty$;*
- (2) *the horizontal lines $\tilde{y} = q$, when $\tilde{\theta}_0 = q$ and a) $\tilde{\theta}_1 = 0$ and any value of $\tilde{\theta}_2$ or b) any value of $\tilde{\theta}_1$ and $\tilde{\theta}_2 \rightarrow \infty$;*
- (3) *the horizontal line discontinuous in $\tilde{x} = 0$ $\tilde{y} = q + q^* \mathbb{1}_{\tilde{x} > 0}$, when $\tilde{\theta}_0 = q$, $\tilde{\theta}_1 = q^* \tilde{\theta}_2$, $\tilde{\theta}_2 \rightarrow 0$.*

Let us note that these three limit cases correspond to common models in practice. In case 1, the response mean depends linearly on the dose, in case 2 the response mean is independent on the dose and case 3 corresponds to the typical model for homeopathic therapies (where there is a dose-effect only after a null threshold $\tilde{x} = 0$ or $x = a$).

3. MAXIMUM LIKELIHOOD ESTIMATOR

In general, for a design (2) with M design points, the MLE can be found from the sufficient statistics $\bar{y}_i = (y_{i,1} + \dots + y_{i,n_i})/n_i$ (the mean observed response value for each design point x_i , $i = 1, \dots, M$):

$$(6) \quad \hat{\theta}_{ML} = \arg \min_{\theta} \sum_{i=1}^M n_i (\bar{y}_i - \eta(x_i, \theta))^2$$

(see Flournoy et al. (2021)). We search the MLE for a 3-points design

$$\xi = \begin{Bmatrix} x_1 & x_2 & x_3 \\ \omega_1 & \omega_2 & \omega_3 \end{Bmatrix},$$

where $x_1 = a$ and $x_3 = b$.

Note that the D-optimal design (4.2) is a equally supported 3-points design, where $x_2 = x^*(\theta_2)$ given by Eq. (3). The following remark highlights the special role of $x_2 = x^*(\theta_2)$ for the model identification.

Remark 1. Let us note that $x^*(\theta_2)$ is the best choice to identify the right shape (concavity) of the Emax model because it is the point where we observe the intermediate value between the minimum and the maximum mean responses, i.e. $\eta(x^*(\theta_2), \theta) = (\eta(a, \theta) + \eta(b, \theta))/2$. In addition, from Eq. (3) we have that $x^*(\theta_2) \in (a, (a+b)/2)$ since $\theta_2 > -a$.

In what follows, we show that if the three points $(x_i, \bar{y}_i), i = 1, 2, 3$, have an increasing concave shape, that is, the three points lay on an increasing concave curve, then there exists a unique analytic solution of the MLE. Otherwise, the existence of the MLE fails and we can provide the probability of observing data in these different adverse situations.

Lemma 3.1. *If there exists a function η in the limit class of Proposition 2.1 that fits the data better than any Emax model, i.e.,*

$$(7) \quad \text{for any } \theta, \quad \sum_{i=1}^M n_i (\bar{y}_i - \eta(x_i))^2 < \sum_{i=1}^M n_i (\bar{y}_i - \eta(x_i, \theta))^2,$$

then the MLE does not exist.

Proof of Lemma 3.1. For any $\epsilon > 0$, there exists θ such that

$$0 < \sum_{i=1}^M n_i (\bar{y}_i - \eta(x_i))^2 - \sum_{i=1}^M n_i (\bar{y}_i - \eta(x_i, \theta))^2 \leq \epsilon;$$

and hence the minimum of (6) cannot be reached. \square

3.1. Analytic solution of the MLE: Data with increasing concave shape. The mathematical condition of increasing concave shape for the data is given by $\bar{y}_1 < \bar{y}_2 < \bar{y}_3$ and $m_1 > m_2$, where

$$m_1 = \frac{\bar{y}_2 - \bar{y}_1}{x_2 - x_1}, \quad m_2 = \frac{\bar{y}_3 - \bar{y}_1}{x_3 - x_1}.$$

In Figure 1 the geometrical visualization of this condition is displayed.

The following results provide the analytic solution of the unique MLE for the reparametrization given in (4) and for the parameter model (1).

Theorem 3.2. *Under the Emax model and a three points design, if the data have increasing concave shape then the MLE of $\tilde{\theta}$ is given by*

$$\begin{aligned} \tilde{\theta}_{ML,0} &= \bar{y}_1 \\ \tilde{\theta}_{ML,1} &= \frac{m_1 m_2}{m_1 - m_2} (\tilde{x}_3 - \tilde{x}_2) \\ \tilde{\theta}_{ML,2} &= \frac{\bar{y}_3 - \bar{y}_2}{m_1 - m_2} \end{aligned}$$




FIGURE 1. Example of points $(x_i, \bar{y}_i), i = 1, 2, 3$, that have an increasing concave shape. The red curve is the Emax response mean that fits them.

Corollary 3.3. *If the data have increasing concave shape then the MLE of θ is*

$$\begin{aligned}\hat{\theta}_{ML,0} &= \bar{y}_1 - a \frac{m_1 m_2 (b - x_2)}{(\bar{y}_3 - \bar{y}_2) - a(m_1 - m_2)} \\ \hat{\theta}_{ML,1} &= \frac{m_1 m_2}{m_1 - m_2} (b - x_2) + a \frac{m_1 m_2 (b - x_2)}{(\bar{y}_3 - \bar{y}_2) - a(m_1 - m_2)} \\ \hat{\theta}_{ML,2} &= \frac{\bar{y}_3 - \bar{y}_2}{m_1 - m_2} - a.\end{aligned}$$

Proof of Theorem 3.2. Equation (6) can be rewritten in $\tilde{\theta}$ and will be referred in this form during this proof. From this equation, with the new coordinates $\tilde{x} = x - a$, if the system of the three equations $\bar{y}_i = \eta(x_i, \tilde{\theta})$ $i = 1, 2, 3$, that is

$$\begin{aligned}(8a) \quad & \bar{y}_1 = \tilde{\theta}_{ML,0} + \tilde{\theta}_{ML,1} \frac{\tilde{x}_1}{\tilde{x}_1 + \tilde{\theta}_{ML,2}} \\ (8b) \quad & \bar{y}_2 = \tilde{\theta}_{ML,0} + \tilde{\theta}_{ML,1} \frac{\tilde{x}_2}{\tilde{x}_2 + \tilde{\theta}_{ML,2}} \\ (8c) \quad & \bar{y}_3 = \tilde{\theta}_{ML,0} + \tilde{\theta}_{ML,1} \frac{\tilde{x}_3}{\tilde{x}_3 + \tilde{\theta}_{ML,2}}\end{aligned}$$

is solved for a unique $\tilde{\theta}$, then this solution must be a MLE. Recall that $\tilde{x}_1 = 0$, $m_1 = (\bar{y}_2 - \bar{y}_1)/\tilde{x}_2$ and $m_2 = (\bar{y}_3 - \bar{y}_1)/\tilde{x}_3$; then the system (8) is equivalent to

$$\begin{aligned}(8a) \quad & \bar{y}_1 = \tilde{\theta}_{ML,0} \\ (8c - 8a) \quad & \bar{y}_3 - \bar{y}_1 = \tilde{\theta}_{ML,1} \frac{\tilde{x}_3}{\tilde{x}_3 + \tilde{\theta}_{ML,2}} \\ \left(\frac{8c-8a}{8b-8a}\right) \quad & \frac{m_2}{m_1} = \frac{\tilde{x}_2 + \tilde{\theta}_{ML,2}}{\tilde{x}_3 + \tilde{\theta}_{ML,2}} = 1 - \frac{\tilde{x}_3 - \tilde{x}_2}{\tilde{x}_3 + \tilde{\theta}_{ML,2}}\end{aligned}$$

and the thesis follows. □

Proof of Corollary 3.3. Solve (5) in θ and apply Theorem 3.2. □

Remark 2. The mathematical condition of increasing concave shape for the data can be rewritten as a linear inequality $A\bar{\mathbf{y}} < \mathbf{0}$, with

$$A = \begin{pmatrix} \left(\frac{1}{x_2-x_1} - \frac{1}{x_3-x_1}\right) & -\frac{1}{x_2-x_1} & \frac{1}{x_3-x_1} \\ 1 & -1 & 0 \\ 0 & 1 & -1 \end{pmatrix}, \quad \bar{\mathbf{y}} = \begin{pmatrix} \bar{y}_1 \\ \bar{y}_2 \\ \bar{y}_3 \end{pmatrix}.$$

Since $\bar{y}_i \sim N(\eta(x_i, \boldsymbol{\theta}), \frac{\sigma^2}{n_i})$ are independent, we are able to compute numerically the probability of $P(A\bar{\mathbf{y}} < \mathbf{0})$. The first plot in Figure 4 displays the probability that the MLE exists for different values of the central support point x_2 .

We have proved that, for data with increasing concave shape, the graph of $\eta(\cdot, \hat{\boldsymbol{\theta}}_{ML})$ contains the three points (x_i, \bar{y}_i) , $i = 1, 2, 3$ because of system (8). This will not be the case in other scenarios and when (8) is not satisfied, we will always find a function η in the limit class of Proposition 2.1 such that (7) holds. The MLE will not exist by Lemma 3.1.

If we include in the model the limit case when there is no effect of the drug, that is, constant response obtained with $\theta_1 = 0$, then the model is not identifiable: equation (6) may have more than a one minimum. Another limit case, which is also not identifiable, is the linear increasing model (see 2 in Proposition 2.1), that can be included only by a reparametrization.

3.2. Cases when the MLE does not exist. When the data do not exhibit an increasing concave shape, we have two cases

- (1) the data exhibit a concave shape ($m_1 > m_2$) but the three means \bar{y}_i , $i = 1, 2, 3$ are not increasing (see Figure 2);
- (2) the three points have convex shape ($m_1 \leq m_2$).




FIGURE 2. Example of points (x_i, \bar{y}_i) , $i = 1, 2, 3$, that have a concave non-increasing shape. The discontinuous curve given in Proposition 2.1 (case 3), which satisfies (7), is plotted in red.

Case 1: Data with non-increasing concave shape. In this case $m_1 > m_2$, but the assumption $\bar{y}_1 < \bar{y}_2 < \bar{y}_3$ fails.

We start by showing that, in this case, $\bar{y}_2 \geq \bar{y}_3$. In fact, by contradiction, the assumption $\bar{y}_2 < \bar{y}_3$ implies $m_2 > 0$. Hence $m_1 > 0$ which implies that $\bar{y}_1 < \bar{y}_2$ that together with the $\bar{y}_2 < \bar{y}_3$ leads to the contradiction.

The fact that $\bar{y}_2 \geq \bar{y}_3$ is opposite to the expected response from the Emax model, where $\eta(x_2, \theta) < \eta(x_3, \theta)$. This fact implies that any curve from the Emax model will fit the two points (x_2, \bar{y}_2) and (x_3, \bar{y}_3) worse than a specific horizontal line. Mathematically speaking, apply Lemma A.3 with $(x_*, y_*) = (x_2, \bar{y}_2)$, $(x^*, y^*) = (x_3, \bar{y}_3)$, $z_* = \eta(x_2, \theta)$, $z^* = \eta(x_3, \theta)$, $n_* = n_2$ and $n^* = n_3$ obtaining

$$(10) \quad \begin{aligned} n_2 (\bar{y}_2 - \eta(x_2, \theta))^2 + n_3 (\bar{y}_3 - \eta(x_3, \theta))^2 &> \min_c \sum_{i=2,3} n_i (\bar{y}_i - c)^2, \\ &= \sum_{i=2,3} n_i (\bar{y}_i - \bar{y}_{23})^2, \end{aligned}$$

where

$$\bar{y}_{23} = \frac{n_2 \bar{y}_2 + n_3 \bar{y}_3}{n_2 + n_3}.$$

Therefore, the minimum in (6) depends on the position of \bar{y}_1 with respect to \bar{y}_{23} :

1.a When $\bar{y}_1 < \bar{y}_{23}$, the function

$$(11) \quad \eta(x) = \begin{cases} \bar{y}_1 & \text{if } x = x_1 = a; \\ \bar{y}_{23} & \text{if } x \in (x_1, b]; \end{cases}$$

satisfies (7) and η belongs to the limit class of the Emax model (see 3 in Proposition 2.1).

1.b When $\bar{y}_1 \geq \bar{y}_{23}$, the horizontal line

$$(12) \quad y = \bar{y}, \quad \text{where } \bar{y} = \frac{n_1 \bar{y}_1 + n_2 \bar{y}_2 + n_3 \bar{y}_3}{n_1 + n_2 + n_3}$$

satisfies (7) and η belongs to the limit class of the Emax model (see 2 in Proposition 2.1).

By Lemma 3.1, the MLE does not exist in both subcases.

Remark 3. The mathematical condition of Subcase 1.a (non-increasing concave shape with $\bar{y}_1 < \bar{y}_{23}$) can be rewritten as a linear inequality $A\bar{\mathbf{y}} < \mathbf{0}$, with

$$A = \begin{pmatrix} \frac{1}{x_2 - x_1} - \frac{1}{x_3 - x_1} & -\frac{1}{x_2 - x_1} & \frac{1}{x_3 - x_1} \\ 1 & -\frac{n_2}{n_2 + n_3} & -\frac{n_3}{n_2 + n_3} \\ 0 & -1 & 1 \end{pmatrix}, \quad \bar{\mathbf{y}} = \begin{pmatrix} \bar{y}_1 \\ \bar{y}_2 \\ \bar{y}_3 \end{pmatrix},$$

while the mathematical condition of Subcase 1.b (non-increasing concave shape with $\bar{y}_1 \geq \bar{y}_{23}$) can be rewritten as $A\bar{\mathbf{y}} < \mathbf{0}$, with

$$A = \begin{pmatrix} \frac{1}{x_2 - x_1} - \frac{1}{x_3 - x_1} & -\frac{1}{x_2 - x_1} & \frac{1}{x_3 - x_1} \\ -1 & +\frac{n_2}{n_2 + n_3} & +\frac{n_3}{n_2 + n_3} \\ 0 & -1 & 1 \end{pmatrix}, \quad \bar{\mathbf{y}} = \begin{pmatrix} \bar{y}_1 \\ \bar{y}_2 \\ \bar{y}_3 \end{pmatrix}.$$

In both subcases, $\bar{y}_i \sim N(\eta(x_i, \theta), \frac{\sigma^2}{n_i})$ are independent and the probabilities can be computed. The bottom left plot in Figure 4 displays the probability that the MLE fails (as a function of the central support point x_2) due to non-increasing concave data.

Proof of Subcase 1.a ($\bar{y}_1 < \bar{y}_{23}$). In this case, for any θ , by (10) we obtain

$$\begin{aligned} \sum_{i=1}^3 n_i (\bar{y}_i - \eta(x_i, \theta))^2 &> \sum_{i=2,3} n_i (\bar{y}_i - \eta(x_i, \theta))^2 \\ &> \sum_{i=2,3} n_i (\bar{y}_i - \bar{y}_{23})^2 = \sum_{i=1}^3 n_i (\bar{y}_i - \eta(x_i))^2, \end{aligned}$$

where η is defined in equation (11). \square

Proof of Subcase 1.b ($\bar{y}_1 \geq \bar{y}_{23}$). Equation (25) with $y_* = \bar{y}_2$, $y^* = \bar{y}_3$, $z_* = \eta(x_2, \theta)$, $z^* = \eta(x_3, \theta)$, $n_* = n_2$ and $n^* = n_3$ gives

$$\begin{aligned} (13) \quad \sum_{i=1,2,3} n_i (\bar{y}_i - \eta(x_i, \theta))^2 &= n_1 (\bar{y}_1 - \eta(x_1, \theta))^2 + \sum_{i=2,3} n_i (\bar{y}_i - \eta(x_i, \theta))^2 \\ &> n_1 (\bar{y}_1 - \eta(x_1, \theta))^2 + \sum_{i=2,3} n_i \left(\bar{y}_i - \frac{n_2 \eta(x_2, \theta) + n_3 \eta(x_3, \theta)}{n_2 + n_3} \right)^2. \end{aligned}$$

Let $\bar{\eta}_{23}(\theta) = \frac{n_2 \eta(x_2, \theta) + n_3 \eta(x_3, \theta)}{n_2 + n_3}$, the monotonicity of Emax model for $\theta_1 > 0$ implies that $\eta(x_1, \theta) < \bar{\eta}_{23}(\theta)$. We have to prove that, for any θ , there exists a constant $c = c(\theta)$ such that

$$(14) \quad \sum_{i=1,2,3} n_i (\bar{y}_i - \eta(x_i, \theta))^2 > \sum_{i=1,2,3} n_i (\bar{y}_i - c(\theta))^2.$$

Two cases:

- $\bar{\eta}_{23}(\theta) \leq \bar{y}_1$: in this case $\eta(x_1, \theta) < \bar{\eta}_{23}(\theta) \leq \bar{y}_1$, then $(\bar{y}_1 - \eta(x_1, \theta))^2 > (\bar{y}_1 - \bar{\eta}_{23}(\theta))^2$. By equation (13), we obtain

$$\sum_{i=1,2,3} n_i (\bar{y}_i - \eta(x_i, \theta))^2 > \sum_{i=1,2,3} n_i (\bar{y}_i - \bar{\eta}_{23}(\theta))^2.$$

- $\bar{\eta}_{23}(\theta) > \bar{y}_1$: the assumption of Subcase 1.b implies $\bar{\eta}_{23}(\theta) > \bar{y}_1 \geq \bar{y}_{23}$. Since $f(c) = \sum_{i=2,3} n_i (\bar{y}_i - c)^2$ is a parabola with minimum in \bar{y}_{23} , then $f(\bar{\eta}_{23}(\theta)) > f(\bar{y}_1)$. Hence by (13)

$$\sum_{i=1,2,3} n_i (\bar{y}_i - \eta(x_i, \theta))^2 > (\bar{y}_1 - \eta(x_1, \theta))^2 + f(\bar{y}_1) \geq \sum_{i=1,2,3} n_i (\bar{y}_i - \bar{y}_1)^2.$$

By (14)

$$\sum_{i=1,2,3} n_i (\bar{y}_i - \eta(x_i, \theta))^2 > \min_c \sum_{i=1,2,3} n_i (\bar{y}_i - c)^2 = \sum_{i=1,2,3} n_i (\bar{y}_i - \bar{y})^2,$$

where \bar{y} is the weighted mean of \bar{y}_i , $i = 1, 2, 3$ and thus, Equation (12) holds. \square

Case 2: Data with convex shape. The fact that the data have convex shape ($m_1 \leq m_2$) is opposite to the expected response from the Emax model, where the response curve exhibits a concave shape. We are going to show that this fact implies that any curve $\eta(x, \theta)$ from the Emax model fits the three points (x_i, \bar{y}_i) $i = 1, 2, 3$ worse than a specific nondecreasing line. Mathematically speaking, this sentence is stated in the following lemma, whose proof is postponed in the sequel. The idea of the proof is drawn in Figure 3.




FIGURE 3. Case 2: the red triangles represent the data (x_i, \bar{y}_i) , $i = 1, 2, 3$, that exhibit a convex shape. η (blue dash-dotted line) is a concave increasing curve that might fit the data. The black straight line fits the three red-triangles better than η (see Lemma 3.4).

Lemma 3.4. Assume $m_1 \leq m_2$. For any concave function $\eta : \mathcal{X} \rightarrow \mathbb{R}$, there exist a line $y = m(\eta)x + q(\eta)$ such that

$$(15) \quad \sum_{i=1,2,3} n_i (\bar{y}_i - \eta(x_i))^2 \geq \sum_{i=1,2,3} n_i [\bar{y}_i - (m(\eta)x_i + q(\eta))]^2,$$

the equality being possible only when η is a segment so that $\eta(x) \equiv (m(\eta)x_i + q(\eta))$ on \mathcal{X} .

Moreover, $m(\eta)$ may be chosen not less than the left derivative of η in x_3 .

Let $\eta_0(x) = m_0x + q_0$ be the ordinary weighted simple linear regressor of (x_i, \bar{y}_i) $i = 1, 2, 3$ —that is the simple linear regressor of the original data—.

$m_0 > 0$. Equation (7) is satisfied with $\eta_0(x)$, since, by Lemma 3.4

$$\begin{aligned} \sum_{i=1,2,3} n_i (\bar{y}_i - \eta(x_i, \theta))^2 &> \sum_{i=1,2,3} n_i [\bar{y}_i - (m(\eta)x_i + q(\eta))]^2 \\ &\geq \sum_{i=1,2,3} n_i (\bar{y}_i - \eta_0(x_i))^2. \end{aligned}$$

Moreover, η_0 belongs to the limit class of the Emax model (see 1 in Proposition 2.1).

$m_0 \leq 0$. Note that all the lines in (15) have $m(\eta) \geq 0$ by Lemma 3.4, since $\eta(x, \theta)$ is increasing, and hence the left derivative of $\eta(x, \theta)$ in x_3 is positive. Then, by Corollary A.2, for any θ there exists a constant $c(\theta)$ such that

$$\sum_{i=1,2,3} n_i [\bar{y}_i - (m(\eta)x_i + q(\eta))]^2 \geq \sum_{i=1,2,3} n_i (\bar{y}_i - c(\theta))^2,$$

so that, by Lemma 3.4,

$$\sum_{i=1,2,3} n_i (\bar{y}_i - \eta(x_i, \theta))^2 > \min_c \sum_{i=1,2,3} n_i (\bar{y}_i - c)^2 = \sum_{i=1,2,3} n_i (\bar{y}_i - \bar{y})^2.$$

Equation (12) holds with $y = \bar{y}$ which belongs to the limit class of the Emax model (see 2 in Proposition 2.1).

By Lemma 3.1, the MLE does not exist.

Remark 4. The mathematical condition of data with convex shape (Case 2) can be rewritten as a linear inequality $A\bar{y} < \mathbf{0}$, with where

$$P(m_1 \leq m_2) = P\left(\left(\frac{1}{x_2-x_1} - \frac{1}{x_3-x_1}\right)\bar{y}_1 - \frac{1}{x_2-x_1}\bar{y}_2 + \frac{1}{x_3-x_1}\bar{y}_3 \geq 0\right)$$

where $\bar{y}_i \sim N(\eta(x_i, \theta), \frac{\sigma^2}{n_i})$ are independent. The bottom right plot in Figure 4 displays the probability that the MLE fails (as a function of the central support point x_2) due to convex data.




FIGURE 4. Probability that the MLE exists [top figure, see Remark 2], and that the MLE does not due to Case 1 and Case 2, respectively [bottom left and right figures, see Remarks 3 and 4], as a function of the central point x_2 for different values of θ_2^t , where $\theta_0^t = 2$, $\theta_1^t = 0.467$, $a = 0.001$, $b = 150$, $\sigma = 0.1$, $n_i = 6$ (with $i = 1, 2, 3$). The dot on the curves corresponds to the D-optimal central point $x^*(\theta_2^t)$.

Proof of Lemma 3.4. Let $\zeta : \mathcal{X} \rightarrow \mathbb{R}$ be the convex function whose graph is obtained with the segments that link (x_1, \bar{y}_1) with (x_2, \bar{y}_2) and (x_2, \bar{y}_2) with (x_3, \bar{y}_3) , i.e.

$$\zeta(x) = \sup\{f : \mathcal{X} \rightarrow \mathbb{R} \text{ such that } f \text{ is convex and } f(x_i) \leq \bar{y}_i, i = 1, 2, 3\}.$$

Denote with $\text{graph}(\eta)$ and $\text{graph}(\zeta)$ the graphs of η and ζ , respectively. The main idea of this proof is to find a line $y = mx + q$ that “separates” $\text{graph}(\eta)$ from $\text{graph}(\zeta)$, that means that

$$(16) \quad \forall x \in \mathcal{X}, \quad \eta(x) \leq mx + q \leq \zeta(x) \quad \text{or} \quad \zeta(x) \leq mx + q \leq \eta(x).$$

Condition (16) is sufficient to state (15). Note that, if $\text{graph}(\eta)$ is not a segment, then at least one of the two points $(x_1, \eta(x_1))$ or $(x_3, \eta(x_3))$ does not belong to the line $y = mx + q$, and hence (15) is strict. We then prove (16) in different cases.

Case when η and ζ are separated (see Figure 3 top-left plot)

Assume that $\eta \leq \zeta$ on \mathcal{X} or, viceversa, $\zeta \leq \eta$ on \mathcal{X} . Then the convex hulls of their graphs are also separated. The hyperplane separation theorem ensures the existence of a line $y(x) = mx + q$ that weakly separates the two closed hulls, so that, in this case a) $\forall x \in \mathcal{X}, \eta(x) \leq mx + q \leq \zeta(x)$ or b) $\forall x \in \mathcal{X}, \zeta(x) \leq mx + q \leq \eta(x)$. Denote by L_{x_3} the left derivative of η in x_3 and observe that it bounds from below any left and right derivatives of η , since η is concave. Assume $m < L_{x_3}$. If a), then the line $y - (mx_3 + q) = L_{x_3}(x - x_3)$ also separates η and ζ as well as, in case b), the line $y - (mx_1 + q) = L_{x_3}(x - x_1)$ does.

Case when η and ζ are not separated

In this case there exist two values $x_*, x^* \in \mathcal{X}$ such that $\eta(x_*) < \zeta(x_*)$ and $\eta(x^*) > \zeta(x^*)$. The Bolzano’s Theorem ensures the existence of an interior point $x_o \in (x_1, x_3)$ such that $\eta(x_o) = \zeta(x_o)$. Note that it is not possible that there are more than two intersecting points between η and ζ , that are not separated and concave and convex, respectively. Finally, we will find the separating line $y = mx + q$ by connecting two points of η , and then its slope cannot be less than the left derivative of η in x_3 .

Subcase: $x_o \in (x_1, x_3)$ the only point in common between the not separated η and ζ (see Figure 3 top-right plot)

Depending on the reciprocal position of η and ζ we can have a) $\bar{y}_3 < \eta(x_3)$ and $\bar{y}_1 > \eta(x_1)$ or b) $\bar{y}_1 < \eta(x_1)$ and $\bar{y}_3 > \eta(x_3)$. If a) the line $y = mx + q$ connecting $(x_o, \eta(x_o))$ and $(x_3, \eta(x_3))$ separates η and ζ . If b) the line $y = mx + q$ connecting $(x_o, \eta(x_o))$ and $(x_1, \eta(x_1))$ separates as before η and ζ .

Subcase: x_o, x^o two distinct points in common between the not separated η and ζ (see Figure 3 bottom-left plot)

The line $y = mx + q$ connecting the two common points separates the two graphs η and ζ , and the proof is concluded. \square

4. SCORE MODIFICATION ACCORDING TO FIRTH’S THEORY

To overcome the unlucky cases described in Section 3.2, we provide Firth’s modification of the score function for the Emax model. In fact, the solution of the Firth modified score sometimes provides a finite estimate when MLE fails, see for instance Kosmidis and Firth (2009b,a). In developing explicit applications, both Firth and Kosmidis have focused on categorical response models (e.g., Kosmidis and Firth (2011); Kosmidis (2017); Kosmidis and Firth (2021); Köll et al. (2021)). For exponential families in canonical parameterization, Firth (1993) showed that his modified score equations are equivalent to maximizing the likelihood penalized with Jefferys invariant prior (Jefferys, 1946).




FIGURE 5. Case 1: data with non-increasing concave shape. The black line represents the true Emax model that generates the sample data (black dots). The red star points are the sample means (\bar{y}_i) at the experimental points x_i , ($i = 1, 2, 3$). The blue curve displays the hyperbole that fits the three points (x_i, \bar{y}_i) , $i = 1, 2, 3$ (i.e. model (1) without any parametric constraint). The discontinuous curve given in (11), which satisfies (7), is plotted in red.




FIGURE 6. Case 2: data with convex shape. The black line represents the true Emax model that generates the sample data (black dots). The red star points are the sample means (\bar{y}_i) at the experimental points x_i , ($i = 1, 2, 3$). The blue curve displays the hyperbole that fits the three points (x_i, \bar{y}_i) , $i = 1, 2, 3$ (i.e. model (1) without any parametric constraint). The simple linear regression of the original data, which satisfies (7), is plotted in red. The light blue dashed-curve represents the Emax model that corresponds to the Firth-modified estimator.

4.1. **The Score Vector.** In a regression model with normal errors $\varepsilon_i = y_i - \eta(x_i, \theta)$, $i = 1, \dots, n$, the score vector $\mathbf{U} = \nabla \ln \mathcal{L}_n(\theta; y, x)$ is

$$\mathbf{U} = \frac{1}{\sigma^2} \sum_{i=1}^n [y_i - \eta(x_i, \theta)] \nabla \eta(x_i, \theta),$$

where, for the Emax model (1),

$$\nabla \eta(x_i, \theta) = \left(1, \frac{x_i}{x_i + \theta_2}, \frac{-\theta_1 x_i}{(x_i + \theta_2)^2} \right)^T,$$

as shown in Dette et al. (2010).

Now suppose the t -th component U_t of the score vector \mathbf{U} is adjusted to

$$(17) \quad U_t^* = U_t + A_t, \quad t = 1, \dots, p,$$

where

$$(18) \quad A_t = \frac{1}{2} \text{trace}\{I^{-1}(P_t + Q_t)\},$$

$$(19) \quad P_t = E(\mathbf{U}\mathbf{U}^T U_t) \quad \text{and} \quad Q_t = E(-O U_t);$$

O and I denote the observed and expected (Fisher) information matrices on the p -dimensional vector θ , respectively. More specifically, the ij -th element of the observed matrix information O is $-\frac{\partial^2}{\partial \theta_i \partial \theta_j} \ln \mathcal{L}_n(\theta; y, x)$, which for the Emax model (1) is

$$O = \frac{1}{\sigma^2} \sum_{i=1}^n \begin{pmatrix} 1 & \frac{x_i}{\theta_2 + x_i} & \frac{-\theta_1 x_i}{(\theta_2 + x_i)^2} \\ \frac{x_i}{\theta_2 + x_i} & \frac{x_i^2}{(\theta_2 + x_i)^2} & \frac{x_i}{(\theta_2 + x_i)^2} (y_i - \theta_0 - 2\theta_1 \frac{x_i}{\theta_2 + x_i}) \\ \frac{-\theta_1 x_i}{(\theta_2 + x_i)^2} & \frac{x_i}{(\theta_2 + x_i)^2} (y_i - \theta_0 - 2\theta_1 \frac{x_i}{\theta_2 + x_i}) & \frac{3\theta_1^2 x_i^2}{(\theta_2 + x_i)^4} - \frac{2\theta_1 x_i (y_i - \theta_0)}{(\theta_2 + x_i)^3} \end{pmatrix}.$$

The expected information matrix $I = E(O)$ is

$$I = \frac{1}{\sigma^2} \sum_{i=1}^n \begin{pmatrix} 1 & \frac{x_i}{\theta_2 + x_i} & -\theta_1 \frac{x_i}{(\theta_2 + x_i)^2} \\ \frac{x_i}{\theta_2 + x_i} & \frac{x_i^2}{(\theta_2 + x_i)^2} & \frac{-\theta_1 x_i^2}{(\theta_2 + x_i)^3} \\ \frac{-\theta_1 x_i}{(\theta_2 + x_i)^2} & \frac{-\theta_1 x_i^2}{(\theta_2 + x_i)^3} & \frac{\theta_1^2 x_i^2}{(\theta_2 + x_i)^4} \end{pmatrix}.$$

Lemma 4.1. *In a non-linear model with normal errors, $P_t = 0$, A_t in (18) reduces to*

$$A_t = \frac{1}{2} \text{trace}(I^{-1} Q_t).$$

4.2. **Score Modification A_t .** The following theorem provides the the score modifications for the Emax model.

Theorem 4.2. *For the Emax model, the score modifications A_t , $t = 1, 2, 3$ are*

$$\begin{aligned} A_1 &= \frac{1}{\theta_1 D} (V_{1,1} M_{1,3} - \text{Cov}_{12} M_{1,2}) \\ A_2 &= \frac{1}{\theta_1 D} (V_{1,1} M_{2,4} - \text{Cov}_{12} M_{2,3}) \\ A_3 &= -\frac{1}{D} (V_{1,1} M_{2,5} - \text{Cov}_{12} M_{2,4}). \end{aligned}$$

where for $l_1 = 1, 2$ and $l_2 = 1, \dots, 5$

$$M_{l_1, l_2} = E_{\xi} \left[\frac{x_i^{l_1}}{(\theta_2 + x_i)^{l_2}} \right]; \quad V_{l_1, l_2} = \text{Var}_{\xi} \left[\frac{x_i^{l_1}}{(\theta_2 + x_i)^{l_2}} \right] = M_{2l_1, 2l_2} - M_{l_1, l_2}^2;$$

and

$$\text{Cov}_{12} = \text{Cov}_{\xi} \left[\frac{x_i}{(\theta_2 + x_i)}, \frac{x_i}{(\theta_2 + x_i)^2} \right] = M_{2,3} - M_{1,1} M_{1,2}; \quad D = V_{1,1} V_{1,2} - \text{Cov}_{12}^2.$$

Proof. From equation (19), after some computation, we have that all items in the matrices $Q_t = \{Q_{t(i,j)}\}_{i,j=1,2,3}$, $t = 1, 2, 3$, are null except those in positions (2, 3) and (3, 3). Specifically,

$$(20) \quad Q_{t(i,j)} = 0 \quad \text{for } (i, j) \neq (2, 3) \text{ or } (3, 3) \text{ and } t = 1, 2, 3$$

while

$$\begin{aligned} Q_{1(2,3)} &= -\frac{1}{\sigma^2} \sum_{i=1}^n \frac{x_i}{(x_i + \theta_2)^2} = -\frac{n}{\sigma^2} M_{1,2}; \\ Q_{1(3,3)} &= \frac{2\theta_1}{\sigma^2} \sum_{i=1}^n \frac{x_i}{(x_i + \theta_2)^3} = \frac{2n\theta_1}{\sigma^2} M_{1,3}; \\ Q_{2(2,3)} &= -\frac{1}{\sigma^2} \sum_{i=1}^n \frac{x_i^2}{(x_i + \theta_2)^3} = -\frac{n}{\sigma^2} M_{2,3}; \\ Q_{2(3,3)} &= \frac{2\theta_1}{\sigma^2} \sum_{i=1}^n \frac{x_i^2}{(x_i + \theta_2)^4} = \frac{2n\theta_1}{\sigma^2} M_{2,4}; \\ Q_{3(2,3)} &= \frac{\theta_1}{\sigma^2} \sum_{i=1}^n \frac{x_i^2}{(x_i + \theta_2)^4} = \frac{n\theta_1}{\sigma^2} M_{2,4}; \\ Q_{3(3,3)} &= -\frac{2\theta_1^2}{\sigma^2} \sum_{i=1}^n \frac{x_i^2}{(x_i + \theta_2)^5} = -\frac{2n\theta_1^2}{\sigma^2} M_{2,5}. \end{aligned}$$

It follows from Lemma 4.1 for the Emax model, that

$$(21) \quad A_t = \frac{1}{2} \text{trace}(I^{-1} Q_t) = I_{(2,3)}^{-1} Q_{t(2,3)} + \frac{1}{2} I_{(3,3)}^{-1} Q_{t(3,3)},$$

where $I_{(i,j)}^{-1}$ denotes the (i, j) -th element of the matrix I^{-1} and the second equality follows from (20). The computation of A_t , $t = 1, 2, 3$, requires only the elements in

positions (2, 3) and (3, 3) of the inverse of the Fisher information matrix. Therefore, we have partitioned I as follows

$$(22) \quad I = \begin{pmatrix} \bar{I}_{11} & \bar{I}_{12} \\ \bar{I}_{21} & \bar{I}_{22} \end{pmatrix},$$

where

$$\bar{I}_{11} = \frac{n}{\sigma^2}, \quad \bar{I}_{21} = \frac{1}{\sigma^2} \begin{pmatrix} \sum_{i=1}^n \frac{x_i}{\theta_2 + x_i} \\ -\theta_1 \sum_{i=1}^n \frac{x_i}{(\theta_2 + x_i)^2} \end{pmatrix} = \frac{n}{\sigma^2} \begin{pmatrix} M_{1,1} \\ -\theta_1 M_{1,2} \end{pmatrix}, \quad \bar{I}_{12} = \bar{I}_{21}^T \text{ and}$$

$$\bar{I}_{22} = \frac{1}{\sigma^2} \begin{pmatrix} \sum_{i=1}^n \frac{x_i^2}{(\theta_2 + x_i)^2} & -\theta_1 \sum_{i=1}^n \frac{x_i^2}{(\theta_2 + x_i)^3} \\ -\theta_1 \sum_{i=1}^n \frac{x_i^2}{(\theta_2 + x_i)^3} & \theta_1^2 \sum_{i=1}^n \frac{x_i^2}{(\theta_2 + x_i)^4} \end{pmatrix} = \frac{n}{\sigma^2} \begin{pmatrix} M_{2,2} & -\theta_1 M_{2,3} \\ -\theta_1 M_{2,3} & \theta_1^2 M_{2,4} \end{pmatrix}.$$

From (22), the following formula for I^{-1} applies:

$$I^{-1} = \begin{pmatrix} \bar{I}^{11} & \bar{I}^{12} \\ \bar{I}^{21} & \bar{I}^{22} \end{pmatrix},$$

where $\bar{I}^{12} = \bar{I}^{21T}$,

$$(23) \quad \begin{aligned} \bar{I}^{11} &= \bar{I}_{11}^{-1} + \bar{I}_{11}^{-1} \bar{I}_{12} \bar{I}^{22} \bar{I}_{21} \bar{I}_{11}^{-1}, \\ \bar{I}^{21} &= -\bar{I}^{22} \bar{I}_{21} \bar{I}_{11}^{-1}, \\ \bar{I}^{22} &= (\bar{I}_{22} - \bar{I}_{21} \bar{I}_{11}^{-1} \bar{I}_{12})^{-1}. \end{aligned}$$

From (23), after some algebra, one obtains

$$\bar{I}^{22} = \begin{pmatrix} \bar{I}_{(2,2)}^{-1} & \bar{I}_{(2,3)}^{-1} \\ \bar{I}_{(3,2)}^{-1} & \bar{I}_{(3,3)}^{-1} \end{pmatrix} = \frac{\sigma^2}{n \theta_1^2 D} \begin{pmatrix} \theta_1^2 V_{1,2} & \theta_1 \text{Cov}_{12} \\ \theta_1 \text{Cov}_{12} & V_{1,1} \end{pmatrix}.$$

Substituting the expressions

$$\bar{I}_{(2,3)}^{-1} = \frac{\sigma^2}{n \theta_1 D} \text{Cov}_{12} \quad \text{and} \quad \bar{I}_{(3,3)}^{-1} = \frac{\sigma^2}{n \theta_1^2 D} V_{1,1}$$

into $\bar{Q}_{t(2,3)}$ and $\bar{Q}_{t(3,3)}$ in (21), we obtain:

$$\begin{aligned} A_1 &= \frac{1}{\theta_1 D} (V_{1,1} M_{1,3} - \text{Cov}_{12} M_{1,2}) \\ A_2 &= \frac{1}{\theta_1 D} (V_{1,1} M_{2,4} - \text{Cov}_{12} M_{2,3}) \\ A_3 &= -\frac{1}{D} (V_{1,1} M_{2,5} - \text{Cov}_{12} M_{2,4}). \end{aligned}$$

□

Note that the modification $\mathbf{A} = (A_1, A_2, A_3)^T$ of the score vector depends on θ_1 and θ_2 . Furthermore, it is a function of the design ξ which enables us to explore the impact of the design choice on the modified score $\mathbf{U}^* = (U_1^*, U_2^*, U_3^*)^T$.

Remark 5. In the Emax model, the derivative matrix of \mathbf{U}^* expressed in (17) is not symmetric and hence there is no penalized likelihood corresponding to the modified score U_t^* .

5. FIRTH'S MODIFICATION AND DESIGN-BASED SOLUTION, FOR CASES 1 AND 2

In this section, at first we explore if the score modification proposed by Firth overcomes the non-existence of the MLE (in Cases 1 and 2) by providing admissible solutions of $\mathbf{U}^* = \mathbf{0}$. To simulate the data we fix $a = 0.001$, $b = 150$, $\theta_0^t = 2$, $\theta_1^t = 0.467$, $\theta_2^t = 50$, and $\sigma = 0.1$ as in Dette et al. Dette et al. (2012). We generate 6 responses at the experimental conditions $x_1 = a$, $x_2 = x^*(\theta_2)$ and $x_3 = b$, and we compute the sample means \bar{y}_1 , \bar{y}_2 and \bar{y}_3 . When these sample data are not in an increasing concave shape, the MLE cannot be computed and we try to compute the Firth's modified estimate. We replicate the above computations $N = 10000$ times with the goal of computing the proportion of times:

- that the MLE exists;
- that we are in Case 1 and that Firth's correction succeeds in finding an admissible estimate;
- that we are in Case 2 and that Firth's correction succeeds in finding an admissible estimate.

To explore the dependence of these proportions on the choice of the guessed value of θ_2 , say θ_2^g , we replicate the above simulation study for $\theta_2^g \in \{12.5, 25, 50, 75, 100\}$.

Table 1 displays the simulation results. From the second column we can immediately observe that the proportion of times that the MLE exists is consistent with the theoretical probability (given in Remark 2) which is reported in parenthesis. The same consistency is displayed in columns 3 and 5, for Case 1 and Case 2, respectively.

It is worth noting that Firth's modification of the score function provides an admissible estimate in Case 2 (see column 6). Case 1 instead remains unsolved, as

| Nominal θ_2 | Pr(MLE exists) | | Firth's success | | Firth's success |
|-----------------------|-----------------|---------------|-----------------|-----------------|-----------------|
| | Pr(MLE exists) | Pr(Case 1) | (Case 1) | Pr(Case 2) | (Case 2) |
| 12.5 | 84.48% (84.82%) | 0.00% (0.00%) | - | 15.52% (15.18%) | 100.00% |
| 25 | 93.69% (93.74%) | 0.00% (0.01%) | - | 6.31% (6.25%) | 99.84% |
| 50 | 97.50% (97.53%) | 0.10% (0.12%) | 0.00% | 2.40% (2.35%) | 99.58% |
| 75 | 98.12% (98.01%) | 0.44% (0.47%) | 0.00% | 1.44% (1.53%) | 100.00% |
| 100 | 97.91% (97.77%) | 0.85% (0.98%) | 1.18% | 1.24% (1.25%) | 100.00% |

TABLE 1. Proportion of times that the MLE exists (column 2) or does not (columns 3 and 5), with the theoretical probability reported in parenthesis. Columns 4 and 6 display the proportion of times that Firth's correction succeeds in finding an admissible estimate in Cases 1 and 2, respectively.

shown in column 4.

In the next section, we face Case 1 by choosing the experimental point x_2 accordingly to an hypothesis test on θ_2 .

5.1. **Design choice based on an hypothesis test to overcome Case 1.** Let us consider the following hypothesis test:

$$(24) \quad \begin{cases} H_0 : \theta_2 \geq \theta_2^g \\ H_1 : \theta_2 < \theta_2^g \end{cases}$$

where θ_2^g is a guessed value such that $\theta_2^g > -a$. We reject the null hypothesis whenever the data realizes Case 1 (i.e. data with sample response means that display a non-increasing concave shape); in other terms, the samples in Case 1 constitute the rejection region. Figure 4 provides the power function of this test, $\beta(\theta_2; x_2)$, which is a function of both θ_2 and the experimental condition x_2 . Therefore, given a design point x_2 , the significance level is $\alpha = \beta(\theta_2^g; x_2)$.

Reversing the role between x_2 and α , this last statement can be used by an experimenter to properly choose the value of x_2 that guarantees a specific significance level α . In other terms, by solving for x_2 the equation $\alpha = \beta(\theta_2^g; x_2)$ we obtain




FIGURE 7. Central experimental point x_2 as a function of α , for different θ_2^g (the graph has been obtained by changing x and y in Figure 4). The dots on the curves represent the central points of the D-optimal designs $x_2^*(\theta_2^g)$ given by Equation (3).

the central design point $x_2(\theta_2^g, \alpha)$ that guarantees that the probability of observing a bad sample in Case 1 is small and equal to α . See Figure 7 for a graphical representation of x_2 as a function of α and θ_2^g .

Thus, if H_0 is true, by fixing a low value for α and taking the same proportion of observations at a , x_2 and b , we should be protected from sample responses that do not produce a MLE. Let us observe that the D-optimal choices for x_2 (the dots on the curves of Figure 7) correspond to very low α -values.

If despite the choice of a small α we observe a bad sample (that is a sample in Case 1), this means that H_1 is more likely than H_0 . In this last case, we suggest

to collect other data at another experimental point $a < x_2(\theta_2^{(1)}, \alpha) < x_2(\theta_2^g, \alpha)$, for some $\theta_2^{(1)} < \theta_2^g$ accordingly to Figure 7.

6. PRACTICAL GUIDELINES AND CONCLUSION

Taking into account all the results presented in the previous sections, herein we can provide some simple guidelines to gather data that produce (or are likely to produce) a finite estimate of the parameters of the Emax model.

We suggest to use a D-optimal design, which is equally supported at $x_1 = a$, $x_2 = x^*(\theta_2^g) \in (a, (a+b)/2)$ (see Remark 1) and $x_3 = b$, not only because it leads to the most precise MLE but also because it is a better guarantee of the existence of the MLE itself, as shown in Figure 7.

Once the responses $y_{i1}, \dots, y_{in/3}$ (for $i = 1, 2, 3$) have been observed at x_1, x_2 and x_3 , respectively, we suggest to proceed as follows:

- if the sample means \bar{y}_i (for $i = 1, 2, 3$) display an increasing concave shape, then the MLE can be computed (see Theorem 3.2);
- if the sample means are in convex shape, one should compute the Firth score modification that most likely leads to a finite parameter estimation (see Table 1);
- if the sample means are in non-increasing concave shape, then it is likely that θ_2^g (the guessed value for θ_2) has been chosen too high, therefore, no estimation is expected from Firth correction (see Table 1). In this case, additional observations should be recorded at a new experimental point $x^*(\theta_2^{(1)}) \in (a, x^*(\theta_2^g))$, for some value $\theta_2^{(1)} < \theta_2^g$, as we have the statistical evidence that θ_2^t is significantly smaller than θ_2^g .

We believe that the theoretical contributions presented in this paper not only offer deep insights into the properties of the Emax model, but can also enhance significantly its estimation process in practical applications.

APPENDIX A. AUXILIARY RESULTS

We start by showing a property of the sum of squares of the residual on a generic linear set of functions.

Proposition A.1. *Let (x_i, y_i) , $i = 1, \dots, n$ be n points and let Θ be a linear set of functions, which means that $a\theta_1 + b\theta_2 \in \Theta$ whenever $\theta_1, \theta_2 \in \Theta$. If*

$$\theta_0 = \arg \min_{\theta \in \Theta} \sum_{i=1}^n (y_i - \theta(x_i))^2,$$

then for any $\theta_1 \in \Theta$ and $t \in [-1, 1]$,

$$\sum_{i=1}^n (y_i - \theta_1(x_i))^2 \geq \sum_{i=1}^n \left[y_i - (t\theta_1(x_i) + (1-t)\theta_0(x_i)) \right]^2,$$

and the inequality is strict if $\theta_1 \neq \arg \min_{\theta \in \Theta} \sum_{i=1}^n (y_i - \theta(x_i))^2$ and $t \in (-1, 1)$.

If Θ is a convex set, then the conclusion still holds with $t \in [0, 1]$ and $t \in [0, 1]$ in place of $t \in [-1, 1]$ and $t \in (-1, 1)$.

Corollary A.2. Let (x_i, y_i) , $i = 1, \dots, n$ be n points and let $y = m_0x + q_0$ be the least square linear estimator. Then for any line $y = mx + q$ with $mm_0 \leq 0$, there exists a constant c such that

$$\sum_{i=1}^n [y_i - (mx_i + q)]^2 \geq \sum_{i=1}^n (y_i - c)^2.$$

The inequality is strict if $m \neq m_0$ or $q \neq q_0$.

Lemma A.3. Assume $y_* \geq y^*$, $z_* < z^*$, and two positive numbers n_* and n^* . Then

$$(25) \quad n_*(y_* - z_*)^2 + n^*(y^* - z^*)^2 > n_* \left(y_* - \frac{n_* z_* + n^* z^*}{n_* + n^*} \right)^2 + n^* \left(y^* - \frac{n_* z_* + n^* z^*}{n_* + n^*} \right)^2,$$

and in particular there exists a constant c such that

$$n_*(y_* - z_*)^2 + n^*(y^* - z^*)^2 > n_*(y_* - c)^2 + n^*(y^* - c)^2.$$

Proof of Proposition A.1. Fixed θ_1 and θ_2 , note that

$$\begin{aligned} g(t) &= \sum_{i=1}^n \left[y_i - (t\theta_1(x_i) + (1-t)\theta_0(x_i)) \right]^2 = \sum_{i=1}^n \left[t(\theta_0(x_i) - \theta_1(x_i)) + y_i - \theta_0(x_i) \right]^2 \\ &= t^2 \sum_{i=1}^n (\theta_0(x_i) - \theta_1(x_i))^2 + 2t \sum_{i=1}^n (\theta_0(x_i) - \theta_1(x_i))(y_i - \theta_0(x_i)) + \sum_{i=1}^n (y_i - \theta_0(x_i))^2 \end{aligned}$$

defines a parabola with minimum in $t = 0$, since

$$g(0) = \sum_{i=1}^n (y_i - \theta_0(x_i))^2 = \min_{\theta \in \Theta} \sum_{i=1}^n (y_i - \theta(x_i))^2.$$

Then $g(1) = g(-1)$ and $g(t) < g(1)$ for any $t \in (-1, 1)$ if $g(0) \neq g(1)$. When Θ is only a convex set, t can be chosen in $[0, 1]$ to guarantee that $t\theta_1 + (1-t)\theta_0 \in \Theta$. \square

Proof of Corollary A.2. Apply Proposition A.1 to the set of lines, with $t^* = |m_0|/(|m| + |m_0|)$ ($0/0 = 0$). Since $m|m_0| + m_0|m| = 0$, we get

$$\sum_{i=1}^n [y_i - (mx_i + q)]^2 \geq \sum_{i=1}^n [y_i - (t^*q + (1-t^*)q_0)]^2,$$

which is the thesis with $c = t^*q + (1-t^*)q_0$. \square

Proof of Lemma A.3. Call $\bar{z} = \frac{n_* z_* + n^* z^*}{n_* + n^*}$. We have

$$\begin{aligned} n_*(y_* - z_*)^2 + n^*(y^* - z^*)^2 &= n_*(y_* - \bar{z} + \bar{z} - z_*)^2 + n^*(y^* - \bar{z} + \bar{z} - z^*)^2 \\ &= n_*(y_* - \bar{z})^2 + n^*(y^* - \bar{z})^2 + n_*(\bar{z} - z_*)(2y_* - \bar{z} - z_*) + n^*(\bar{z} - z^*)(2y^* - \bar{z} - z^*). \end{aligned}$$

and then, since

$$\bar{z} - z_* = \frac{n^* z^* - n_* z_*}{n_* + n^*} = n^* \frac{z^* - z_*}{n_* + n^*}, \quad \bar{z} - z^* = \frac{n_* z_* - n^* z^*}{n_* + n^*} = n_* \frac{z_* - z^*}{n_* + n^*},$$

we obtain

$$\begin{aligned}
& \left[n_*(y_* - z_*)^2 + n^*(y^* - z^*)^2 \right] - \left[n_*(y_* - \bar{z})^2 + n^*(y^* - \bar{z})^2 \right] \\
&= n_*n^* \frac{z^* - z_*}{n_* + n^*} (2y_* - \bar{z} - z_*) + n_*n^* \frac{z_* - z^*}{n_* + n^*} (2y^* - \bar{z} - z^*) \\
&= n_*n^* \frac{z^* - z_*}{n_* + n^*} \left(2y_* - \bar{z} - z_* - 2y^* + \bar{z} + z^* \right) \\
&= n_*n^* \frac{z^* - z_*}{n_* + n^*} \left[2(y_* - y^*) + (z^* - z_*) \right],
\end{aligned}$$

which is positive, since $y_* \geq y^*$, $z_* < z^*$ and $n_*, n^* > 0$. \square

REFERENCES

- Atkinson, A. C., A. N. Donev, and R. D. Tobias (2007). *Optimum Experimental Designs, with SAS*, Volume 34 of *Oxford Statistical Science Series*. Oxford University Press, Oxford.
- Baker, J. G. (2010). A full pharmacological analysis of the three turkey β -adrenoceptors and comparison with the human β -adrenoceptors. *PLoS One* 5(11), e15487.
- Baker, M., J. L. Hobman, C. E. R. Dodd, S. J. Ramsden, and D. J. Stekel (2016, 02). Mathematical modelling of antimicrobial resistance in agricultural waste highlights importance of gene transfer rate. *FEMS Microbiology Ecology* 92(4), fiw040.
- Bretz, F., H. Dette, and J. C. Pinheiro (2010). Practical considerations for optimal designs in clinical dose finding studies. *Statistics in medicine* 29(7-8), 731–742.
- Chen, Y., M. Fries, and S. Leonov (2023). Longitudinal model for a dose-finding study for a rare disease treatment. *Statist. Papers* 64(4), 1343–1360.
- Denney, W. S., G. E. Sonnenberg, S. Carvajal-Gonzalez, T. Tuthill, and V. M. Jackson (2017). Pharmacokinetics and pharmacodynamics of pf-05190457: The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects. *British journal of clinical pharmacology* 83(2), 326–338.
- Dette, H., B. Bornkamp, and F. Bretz (2012). On the efficiency of two-stage response-adaptive designs. *Statistics in Medicine* 32(10), 1646–1660.
- Dette, H., C. Kiss, M. Bevanda, and F. Bretz (2010). Optimal designs for the Emax, log-linear and exponential models. *Biometrika* 97(2), 513–518.
- Dragalin, V., B. Bornkamp, F. Bretz, F. Miller, S. K. Padmanabhan, N. Patel, I. Perevozskaya, J. Pinheiro, and J. R. Smith (2010). A simulation study to compare new adaptive dose-ranging designs. *Statistics in Biopharmaceutical Research* 2(4), 487–512.
- Fedorov, V. (1972). *Theory of Optimal Experiments*. New York: Academic Press.
- Fedorov, V. V. and S. L. Leonov (2013). *Optimal Design for Nonlinear Response Models*. CRC Press.
- Firth, D. (1993). Bias reduction of maximum likelihood estimates. *Biometrika* 80(1), 27–38.
- Flournoy, N., C. May, and C. Tommasi (2021). The effects of adaptation on maximum likelihood inference for nonlinear models with normal errors. *Journal of Statistical Planning and Inference* 214, 139–150.

- Flournoy, N., J. Moler, and F. Plo (2020). Performance measures in dose-finding experiments. *International Statistical Review* 88(3), 728–751.
- Han, D. W., O.-J. Linares-Perdomo, J. S. Lee, J. H. Kim, and S. E. Kern (2011). Comparison between cerebral state index and bispectral index as measures of electroencephalographic effects of sevoflurane using combined sigmoidal Emax model. *Acta Pharmacologica Sinica* 32(10), 1208–1214.
- Holford, N. H. and L. B. Sheiner (1981). Understanding the dose-effect relationship. *Clinical pharmacokinetics* 6(6), 429–453.
- Jefferys, J. B. (1946). The denomination and character of shares, 1855-1885. *The economic History review* 16(1), 45–55.
- Köll, S., I. Kosmidis, C. Kleiber, and A. Zeileis (2021). Bias reduction as a remedy to the consequences of infinite estimates in poisson and tobit regression.
- Kosmidis, I. (2017). Multinomial logistic regression using brglm2.
- Kosmidis, I. and D. Firth (2009a). Bias reduction in exponential family nonlinear models. *Biometrika* 96(4), 793–804.
- Kosmidis, I. and D. Firth (2009b). Bias reduction in generalized nonlinear models. University of Warwick, online at https://www.ikosmidis.com/files/ikosmidis_JSM2009.pdf.
- Kosmidis, I. and D. Firth (2011). Multinomial logit bias reduction via the poisson log-linear model. *Biometrika* 98(3), 755–759.
- Kosmidis, I. and D. Firth (2021). Jeffreys-prior penalty, finiteness and shrinkage in binomial-response generalized linear models. *Biometrika* 108(1), 71–82.
- Leonov, S. and S. Miller (2009). An adaptive design for the E_{MAX} model and its application in clinical trials. *Journal of Biopharmaceutical Statistics* 19, 360–385.
- MacDougall, J. (2006). Analysis of dose–response studies? Emax model. In *Dose finding in drug development*, pp. 127–145. Springer.
- Michaelis, L., M. L. Menten, et al. (1913). Die kinetik der invertinwirkung. *Biochem. z* 49(333-369), 352.
- Rath, S., M. Zvidzayi, C. Bon, and I. Kanfer (2022). Application of emax model to assess the potency of topical corticosteroid products. *Basic & Clinical Pharmacology & Toxicology* 131(3), 165–173.
- Silvey, S. (2013). *Optimal Design: An Introduction to the Theory for Parameter Estimation*, Volume 1. Springer Science & Business Media.